Radiation and antibody therapy for bone plasmacytoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of solitary bone plasmacytoma with less than 10% abnormal plasma cells in your bone marrow.
- You should be able to take care of yourself (ECOG 0, 1, or 2).
- You cannot have had any prior treatment for multiple myeloma, except local radiation for the plasmacytoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares giving chemotherapy with radiation versus radiation alone for people with a single plasmacytoma (a localized plasma-cell tumor). It aims to see whether adding chemotherapy improves control of the disease while keeping side effects acceptable.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
This trial tests a new combination of drugs (CM336, isatuximab, bortezomib, and lenalidomide) for people newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this combination can help control the disease better.
Hear when a new Solitary Bone Plasmacytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.